Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Eli Lilly and Company
Modality
UNKNOWN
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05241834CT.gov A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment | — | Active Not Recruiting | — | — | — |
NCT05225259CT.gov Expanded Access for LOXO-260 in Participants With Cancer Caused by an Abnormal RET Gene That Did Not Respond/is no Longer Responding to Treatment With a Type of Drug Called a RET Inhibitor | — | No Longer Available | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Indicative
Detailed axis rationale is planned and will be published soon.
Same indication · Thyroid Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Loxo-260 (this asset) | Eli Lilly and Company | P1 | CC · 43 |
| Pembrolizumab | Kineta Inc. | P2 | BB |
| Alectinib | Hoffmann-La Roche | P2 | B |
| Denosumab | Amgen | P2 | B |
| Sorafenib | National Cancer Institute (NCI) | P2 | B |
| [18F]F-RESCA-T4 | RenJi Hospital | P2/3 | CCC |
| [18f]f-resca-rt4 | RenJi Hospital | P2/3 | CCC |
| [68ga]ga-nota-rt4 | RenJi Hospital | P2/3 | CCC |
| [68ga]ga-nota-t4 | RenJi Hospital | P2/3 | CCC |
+42 more in the Thyroid Cancer cohort
Other indications for Loxo-260
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Lung Carcinoma | — | P1 | C · 37 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Loxo-260 in Thyroid Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/loxo-260-thyroid-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →